Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression

dc.date.accessioned2018-11-29T15:37:00Z
dc.date.accessioned2022-10-18T21:28:16Z
dc.date.available2018-11-29T15:37:00Z
dc.date.available2022-10-18T21:28:16Z
dc.date.created2018-11-29T15:37:00Z
dc.date.issued2017
dc.identifierhttp://hdl.handle.net/10533/228605
dc.identifier1140970
dc.identifierWOS:000397642400033
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4459961
dc.description.abstractClinical studies have suggested a survival benefit in ovarian cancer patients with type 2 diabetes mellitus taking metformin, however the mechanism by which diabetic concentrations of metformin could deliver this effect is still poorly understood. Platel
dc.languageeng
dc.relationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400552/
dc.relationhandle/10533/111556
dc.relation10.18632/oncotarget.15348
dc.relationhandle/10533/111541
dc.relationhandle/10533/108045
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.titleDiabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression
dc.typeArticulo


Este ítem pertenece a la siguiente institución